A Phase 2 interventional study of HTX-011 and Luer Lock applicator in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Heron Therapeutics · Phase 2, Interventional, and Prevention
This is a Phase 2, open-label, multi-cohort study to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of a single, individualized dose of HTX-011 administered into the surgical site as a monotherapy or with other medications to enhance analgesia in subjects undergoing unilateral simple bunionectomy.
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
This study's enrollment of 78 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
Drug: HTX-011 · Device: Luer Lock applicator · Device: Vial access device
HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation; Aprepitant, three single doses of aprepitant will be administered orally.
Drug: HTX-011 · Device: Luer Lock applicator · Device: Vial access device · Drug: aprepitant
HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation and a scheduled multimodal analgesic (MMA) regimen.
Drug: HTX-011 · Device: Luer Lock applicator · Device: Vial access device
Drug pages: Bupivacaine · Meloxicam
HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
Applicator for instillation.
Device for withdrawal of drug product.
Aprepitant, three single doses of aprepitant will be administered orally.
Mean Area Under the Curve (AUC) of the NRS-A (Windowed Worst Observation Carried Forward) Pain Intensity Scores
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded with activity (NRS-A), sitting with the plantar surface of the ball of the surgically attended foot touching the floor (no weight-bearing).
Time frame: 72 hours
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) Through 72 Hours
Time frame: 72 hours
Percentage of Subjects Receiving no Opioid Rescue
Time frame: 72 hours
Percentage of Subjects Receiving no Opioid Rescue
Only subjects in Cohort 3 received a scheduled, non-opioid MMA regimen following surgery.
Time frame: Day 7 and Day 28
Mean Area Under the Curve (AUC) of the NRS-R (Windowed Worst Observation Carried Forward) Pain Intensity Scores
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are measured at rest.
Time frame: 72 hours
| Milestone | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| Started | 30 | 17 | 31 |
| Completed | 30 | 17 | 31 |
| Not completed | 0 | 0 | 0 |
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded with activity (NRS-A), sitting with the plantar surface of the ball of the surgically attended foot touching the floor (no weight-bearing).
| pain intensity score*hr | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| Mean Area Under the Curve (AUC) of the NRS-A (Windowed Worst Observation Carried Forward) Pain Intensity Scores | 278.36 ± 151.085 | 288.23 ± 115.790 | 126.93 ± 129.819 |
| MME, morphine milligram equivalents | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) Through 72 Hours | 11.47 ± 10.198 | 21.88 ± 13.305 | 1.61 ± 3.449 |
| Participants | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| Percentage of Subjects Receiving no Opioid Rescue | 6 | 0 | 24 |
Only subjects in Cohort 3 received a scheduled, non-opioid MMA regimen following surgery.
| Participants | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|
| Day 7 | 24 |
| Day 28 | 24 |
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are measured at rest.
| pain intensity score*hr | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| Mean Area Under the Curve (AUC) of the NRS-R (Windowed Worst Observation Carried Forward) Pain Intensity Scores | 251.92 ± 127.319 | 252.39 ± 112.996 | 113.10 ± 124.696 |
Collected over 42 Days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group 1: HTX-011 | 0/30 (0%) | 0/30 (0%) | 13/30 (43.3%) |
| Treatment Group 2: HTX-011 + Aprepitant | 0/17 (0%) | 1/17 (5.9%) | 13/17 (76.5%) |
| Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | 0/31 (0%) | 0/31 (0%) | 16/31 (51.6%) |
| Event | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| CellulitisInfections and infestations | 0/30 | 1/17 | 0/31 |
| Postoperative abscessInfections and infestations | 0/30 | 1/17 | 0/31 |
| Event | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen |
|---|---|---|---|
| NauseaGastrointestinal disorders | 5/30 | 6/17 | 7/31 |
| ConstipationGastrointestinal disorders | 0/30 | 5/17 | 2/31 |
| HeadacheNervous system disorders | 8/30 | 1/17 | 1/31 |
| PruritusSkin and subcutaneous tissue disorders | 0/30 | 2/17 | 1/31 |
| PyrexiaGeneral disorders | 0/30 | 2/17 | 0/31 |
| VomitingGastrointestinal disorders | 0/30 | 1/17 | 3/31 |
| Decreased appetiteMetabolism and nutrition disorders | 2/30 | 0/17 | 1/31 |
| DizzinessNervous system disorders | 2/30 | 0/17 | 0/31 |
| Localised infectionInfections and infestations | 0/30 | 0/17 | 2/31 |
| Abdominal discomfortGastrointestinal disorders | 0/30 | 1/17 | 2/31 |
| Age, Categorical(Participants) | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 16 | 29 | 75 |
| >=65 years | 0 | 1 | 2 | 3 |
| Age, Continuous(years) | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | Total |
|---|---|---|---|---|
| Mean | 47.3 ± 11.58 | 43.7 ± 14.73 | 49.1 ± 12.66 | 47.2 ± 12.74 |
| Sex: Female, Male(Participants) | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | Total |
|---|---|---|---|---|
| Female | 28 | 13 | 29 | 70 |
| Male | 2 | 4 | 2 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | Total |
|---|---|---|---|---|
| Hispanic or Latino | 15 | 12 | 15 | 42 |
| Not Hispanic or Latino | 15 | 5 | 16 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 4 | 6 |
| White | 28 | 16 | 27 | 71 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Treatment Group 1: HTX-011 | Treatment Group 2: HTX-011 + Aprepitant | Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen | Total |
|---|---|---|---|---|
| United States | 30 | 17 | 31 | 78 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Meloxicam